BRPI0410091A - vacina para vìrus influenza eqüina, e, método para induzir uma resposta imune contra vìrus influenza eqüina - Google Patents

vacina para vìrus influenza eqüina, e, método para induzir uma resposta imune contra vìrus influenza eqüina

Info

Publication number
BRPI0410091A
BRPI0410091A BRPI0410091-3A BRPI0410091A BRPI0410091A BR PI0410091 A BRPI0410091 A BR PI0410091A BR PI0410091 A BRPI0410091 A BR PI0410091A BR PI0410091 A BRPI0410091 A BR PI0410091A
Authority
BR
Brazil
Prior art keywords
vaccine
influenza virus
virus
equine influenza
dna
Prior art date
Application number
BRPI0410091-3A
Other languages
English (en)
Inventor
Alexander Lai
Original Assignee
Univ Oklahoma State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oklahoma State filed Critical Univ Oklahoma State
Publication of BRPI0410091A publication Critical patent/BRPI0410091A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

"VACINA PARA VìRUS INFLUENZA EQüINA, E, MéTODO PARA INDUZIR UMA RESPOSTA IMUNE CONTRA VìRUS INFLUENZA EQüINA". A invenção refere-se a uma vacina de DNA que expressa o gene de hemaglutinina (HA1) do virus influenza eqüina-2. Manipulando-se um códon de interrupção no HA1, assegura-se a expressão de HA1. A encapsulação da vacina de DNA em lipossoma e a inoculação intranasal, é suficiente para elicitar imunidade protetora a uma dosagem significativamente menor se comparada com uma vacina de DNA que expressa o gene HA de comprimento total. Dosagem menor reduz o risco de indução de anticorpos anti-DNA. Inoculação intranasal diretamente nas células epiteliais respiratórias reduz o risco de integração de DNA. A vacina de acordo com a invenção é vantajosa relativamente a vacinas correntes inativadas ou vivas atenuadas, porque a atualização da vacina requer apenas a substituição da seqüência codificadora com o novo vírus.
BRPI0410091-3A 2003-05-15 2004-04-16 vacina para vìrus influenza eqüina, e, método para induzir uma resposta imune contra vìrus influenza eqüina BRPI0410091A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47084303P 2003-05-15 2003-05-15
PCT/US2004/011998 WO2005014778A2 (en) 2003-05-15 2004-04-16 Dna vaccine expressing ha1 of equine-2 influenza virus

Publications (1)

Publication Number Publication Date
BRPI0410091A true BRPI0410091A (pt) 2006-06-06

Family

ID=34135039

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410091-3A BRPI0410091A (pt) 2003-05-15 2004-04-16 vacina para vìrus influenza eqüina, e, método para induzir uma resposta imune contra vìrus influenza eqüina

Country Status (12)

Country Link
US (1) US7244435B2 (pt)
EP (1) EP1623015A4 (pt)
JP (1) JP2007525456A (pt)
KR (1) KR20060035602A (pt)
CN (1) CN1925870A (pt)
AU (1) AU2004263816A1 (pt)
BR (1) BRPI0410091A (pt)
CA (1) CA2523676A1 (pt)
MX (1) MXPA05012199A (pt)
NZ (1) NZ543196A (pt)
WO (1) WO2005014778A2 (pt)
ZA (1) ZA200509187B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
CA2606429A1 (en) * 2005-04-21 2006-11-02 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
KR101484305B1 (ko) * 2006-03-10 2015-01-19 위스콘신 얼럼나이 리서어치 화운데이션 Ｈ3 말 인플루엔자 ａ 바이러스
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
CN101502649B (zh) * 2008-06-23 2011-11-30 深圳职业技术学院 一种脂质体流感疫苗
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CN101886084B (zh) * 2010-03-17 2012-05-30 王世霞 一种密码子优化的h3ha/xj3-07基因及其核酸疫苗
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
BR112013018074A2 (pt) 2011-01-13 2020-12-01 Variation Biotechnologies, Inc. métodos para a preparação de vesículas e formulações produzidas a partir dessas
WO2013072768A2 (en) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
RU2698906C2 (ru) 2012-01-27 2019-09-02 Вэриэйшн Биотекнолоджиз, Инк. Способы и композиции для терапевтических агентов
KR101588334B1 (ko) * 2013-07-02 2016-01-27 대한민국 강독화된 인플루엔자 바이러스 변이주
KR101493613B1 (ko) * 2013-10-25 2015-02-13 위스콘신 얼럼나이 리서어치 화운데이션 Ｈ3 말 인플루엔자 ａ 바이러스

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683137A (en) * 1982-04-16 1987-07-28 Cornell Research Foundation, Inc. Temperature sensitive reassortant viruses and a vaccine against equine influenza
GB8300467D0 (en) * 1983-01-08 1983-02-09 Wellcome Found Equine influenza
US4920213A (en) * 1985-06-20 1990-04-24 Biotechnology Research Partners, Ltd. Method and compositions useful in preventing equine influenza
US4631191A (en) * 1985-06-20 1986-12-23 Biotechnology Research Partners, Ltd. Methods and compositions useful in preventing equine influenza
US4619827A (en) * 1985-10-07 1986-10-28 Neogen Corporation Method for administering equine vaccines and compositions therefor
US4689224A (en) * 1985-10-07 1987-08-25 Neogen Corporation Method for administering vaccines containing equine leukokines and compositions therefor
ZA973642B (en) * 1996-04-26 1997-11-25 Merck & Co Inc DNA vaccine formulations.
AU8392898A (en) * 1997-07-14 1999-02-10 Powerject Vaccines, Inc. Method of dna vaccination using dna encoding antigen and encoding il6
US6482414B1 (en) * 1998-08-13 2002-11-19 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US6177082B1 (en) * 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US6398774B1 (en) * 1999-09-29 2002-06-04 Heska Corporation Intranasal delivery system
US20030008000A1 (en) * 2001-03-08 2003-01-09 Wong Jonathan P. DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus

Also Published As

Publication number Publication date
KR20060035602A (ko) 2006-04-26
EP1623015A4 (en) 2007-10-10
EP1623015A2 (en) 2006-02-08
WO2005014778A2 (en) 2005-02-17
AU2004263816A1 (en) 2005-02-17
CN1925870A (zh) 2007-03-07
WO2005014778A3 (en) 2006-10-05
US7244435B2 (en) 2007-07-17
CA2523676A1 (en) 2005-02-17
US20050032732A1 (en) 2005-02-10
JP2007525456A (ja) 2007-09-06
MXPA05012199A (es) 2006-02-10
ZA200509187B (en) 2007-12-27
NZ543196A (en) 2008-04-30

Similar Documents

Publication Publication Date Title
BRPI0410091A (pt) vacina para vìrus influenza eqüina, e, método para induzir uma resposta imune contra vìrus influenza eqüina
Johansson et al. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response
Liu et al. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections
Liu et al. Recombinant virus-like particles elicit protective immunity against avian influenza A (H7N9) virus infection in ferrets
Pica et al. NS1-truncated live attenuated virus vaccine provides robust protection to aged mice from viral challenge
Tian et al. Protective efficacy of the H5 inactivated vaccine against different highly pathogenic H5N1 avian influenza viruses isolated in China and Vietnam
HUP0400445A2 (hu) Új vakcinakészítmények
DK1618889T3 (da) Influenzavaccine
Cox et al. Development of a mouse-adapted live attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live attenuated influenza virus vaccine
NZ627888A (en) Materials and methods for respiratory disease control in canines
BRPI0512421B8 (pt) Recombinantes de avipox expressando genes do vírus da doença febre aftosa
CN104136456A (zh) 以计算方式优化的h3n2、h2n2和b型流感病毒的广泛反应性抗原
El-Sayed Advances in rabies prophylaxis and treatment with emphasis on immunoresponse mechanisms
ATE352557T1 (de) Rekombinantes nukleoprotein von newcastle- krankheitsvirus als markierungsimpfstoff
Zheng et al. Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48/80 adjuvant
Gambaryan et al. Comparative safety, immunogenicity, and efficacy of several anti‐H5N1 influenza experimental vaccines in a mouse and chicken models (Testing of killed and live H5 vaccine)
Wraith et al. Induction of influenza A virus cross-reactive cytotoxic T cells by a nucleoprotein/haemagglutinin preparation
Chen et al. Efficacy of live-attenuated H9N2 influenza vaccine candidates containing NS1 truncations against H9N2 avian influenza viruses
Ferko et al. Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts
JP2018525028A5 (pt)
Lei et al. Cross-protective immunity of the haemagglutinin stalk domain presented on the surface of Lactococcus lactis against divergent influenza viruses in mice
Hasegawa et al. Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses
MX2021015938A (es) Virus para vacuna contra el síndrome respiratorio y reproductivo porcino.
BR0207761A (pt) Uso de um vìrus leporipox recombinante vivo, vacina, e, vìrus leporipox recombinante vivo
Tao et al. Enhanced protective efficacy of H5 subtype influenza vaccine with modification of the multibasic cleavage site of hemagglutinin in retroviral pseudotypes

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.